MedTrace Logo

Effect of Intraoperative Dexmedetomidine on Early Postoperative Cognitive Dysfunction

NCT03793751 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This study will aim to identify the impact of Intraoperative dexmedetomidine infusion on POCD assessed by the Montreal Cognitive Assessment (MoCA) in geriatric patients above 60 years undergoing hip surgery under spinal anaesthesia.

Conditions

  • Cognitive Dysfunction

Interventions

DRUG

Dexmedetomidine Injection

Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.

Sponsors & Collaborators

  • Tata Main Hospital

    lead OTHER

Principal Investigators

  • Dr.Deb S Nag, MD · Tata Main Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2019-12-01
Completion
2019-12-01

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03793751 on ClinicalTrials.gov